(Q77098012)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

review article

1 reference

title

Treatment of type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

author name string

M N Feinglos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 July 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

2 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

757-790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association

2 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

PROTECT interim results: a large multicenter study of patients with type II diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Acarbose: its role in the treatment of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Acarbose: a review of US clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

An overview of metformin in the treatment of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Chromium oligopeptide activates insulin receptor tyrosine kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Pathogenesis of NIDDM. A balanced overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Gene therapy for diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Clinical profile of glimepiride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Exercise and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Diet and exercise in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Insulin-like growth factor I: physiology, metabolic effects and clinical uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

7 January 2021

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Insulin therapy in type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-d-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Role of metformin accumulation in metformin-associated lactic acidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Comparison of Bedtime NPH or Preprandial Regular Insulin Combined With Glibenclamide in Secondary Sulfonylurea Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Amylin: history and overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Chromium deficiency might contribute to insulin resistance, type 2 diabetes mellitus, dyslipidaemia, and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Long-term comparison of three dietary prescriptions in the treatment of NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Drug therapy of non-insulin-dependent diabetes mellitus in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branched-chain amino acid supplements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Glycemic control in diabetes mellitus: have changes in therapy made a difference?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus. A double-edged sword?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Drugs on the horizon for treatment of type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Human islet allografts in patients with type 2 diabetes undergoing liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Clinical profile of the novel sulphonylurea glimepiride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

High-fat and high-carbohydrate diets and energy balance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Glucose control in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Cardiovascular effects of sulphonylurea derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Contraindications to metformin therapy in patients with NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Potential role of thiazolidinediones in older diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Dietary composition, body weight, and NIDDM. Comparison of high-fiber, high-carbohydrate, and modified-fat diets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970023-7

10.1016/S0025-7125(05)70023-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9706120%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference